Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHC Healthcare GroupTPE:4164 -1.34%77 Debt-to-EBITDA is 5.07 as of Jun. 2026, which is 5% above its 10-year median of 4.84. GuruFocus rates TPE:4164 with a GF Score™ of 77/100 and a GF Value™ of NT$52.72 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 91 Medical Distribution companies, CHC Healthcare Group ranks worse than 78.02% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CHC Healthcare Group's Debt-to-EBITDA or its related term are showing as below:
TPE:4164'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.69 Med: 4.84 Max: 8.71
Current: 4.88
During the past 13 years, the highest Debt-to-EBITDA Ratio of CHC Healthcare Group was 8.71. The lowest was 2.69. And the median was 4.84.
TPE:4164's Debt-to-EBITDA is ranked worse than 78.02% of 91
companies
in the Medical Distribution industry
Industry Median: 2.29
vs TPE:4164: 4.88
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CHC Healthcare Group Debt-to-EBITDA Related Terms
CHC Healthcare Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for CHC Healthcare Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4164 vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, CHC Healthcare Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHC Healthcare Group Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, CHC Healthcare Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CHC Healthcare Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
CHC Healthcare Group (TPE:4164) has a Debt-to-EBITDA of 5.07 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CHC Healthcare Group. This is near median its historical median of 4.84. Over the past decade, CHC Healthcare Group's Debt-to-EBITDA has ranged from 2.69 to 8.71. According to the industry distribution chart, CHC Healthcare Group ranks #71 out of 91 companies in the Medical Distribution industry, placing it in the top 78%.
Is CHC Healthcare Group's Debt-to-EBITDA too high?
CHC Healthcare Group's current Debt-to-EBITDA of 5.07 is near median its 10-year median of 4.84. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 8.71. The Medical Distribution industry median Debt-to-EBITDA is 2.29. CHC Healthcare Group's value of 5.07 is 121.4% above this industry median. Based on the distribution chart, CHC Healthcare Group ranks #71 out of 91 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, CHC Healthcare Group has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CHC Healthcare Group's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, CHC Healthcare Group ranks #71 out of 91 companies for Debt-to-EBITDA. This places CHC Healthcare Group in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. CHC Healthcare Group's value of 5.07 is 121.4% above this benchmark. Historically, CHC Healthcare Group's own Debt-to-EBITDA has ranged from 2.69 to 8.71 over the past decade. While the company's 10-year median is 4.84 vs. the industry median of 2.29, CHC Healthcare Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.29, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CHC Healthcare Group's current Debt-to-EBITDA of 5.07 is 121.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CHC Healthcare Group. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHC Healthcare Group's current Debt-to-EBITDA is 5.07, which is near median its own 10-year median of 4.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHC Healthcare Group stock overvalued right now?
Based on GuruFocus' analysis, CHC Healthcare Group (TPE:4164) is currently considered Possible Value Trap. The stock's GF Value™ is NT$52.72, compared to a current price of NT$25.85 — trading 51% below its estimated fair value. The current Debt-to-EBITDA is 5.07, which is near median its 10-year median of 4.84 and 121.4% above the Medical Distribution industry median of 2.29. CHC Healthcare Group's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CHC Healthcare Group (TPE:4164), the current Debt-to-EBITDA is 5.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CHC Healthcare Group (TPE:4164) Overvalued in 2026?
Based on GuruFocus' analysis, CHC Healthcare Group stock appears to be undervalued.
The current stock price of NT$25.85 is trading 51% below its estimated GF Value™ of NT$52.72.
GuruFocus considers CHC Healthcare Group to be Possible Value Trap.
Key valuation signals for TPE:4164:
Debt-to-EBITDA: 5.07 (near median its 10-year median of 4.84)
GF Value™: NT$52.72 vs. price of NT$25.85 (51% below fair value)
Industry Position: 121.4% above the Medical Distribution median (#71 of 91)
No single metric tells the full story. See the TPE:4164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CHC Healthcare Group is a Taiwan-based company engaged in the trading of pharmaceutical products and health food, as well as the sale, leasing, installation, and repair of medical instruments. It is engaged in the distribution of radiotherapy equipment, including equipment used in radiation oncology, ophthalmology, dentistry, and neuroscience. It also provides medical equipment consulting for hospitals and clinics. It earns revenues from the sale of drugs, the sale of medical instruments, repairs, maintenance, and other services.
77GF Score
Get the complete analysis for TPE:4164
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4164 has been successfully added to your 
